Cardinal Health (CAH) Earnings Date & Reports

Cardinal Health reported third quarter fiscal year 2026 revenue of $60.9 billion, a 11% increase from $54.9 billion in the prior-year period. This topped growth expectations but fell slightly short of the $62.4 billion consensus estimate.

Non-GAAP operating earnings climbed 18% to $956 million, driving non-GAAP diluted EPS to $3.17, up 35% year-over-year and well ahead of the $2.80 consensus. GAAP results showed operating earnings of $509 million, down 30%, and diluted EPS of $1.69, down 20%, primarily due to a $184 million pre-tax goodwill impairment in the Navista & ION reporting unit.

By segment, Pharmaceutical and Specialty Solutions delivered revenue of $56.1 billion (up 11%) and profit of $784 million (up 18%), fueled by brand/specialty sales and generics performance. Global Medical Products and Distribution revenue was flat at $3.1 billion, with profit down 36% to $25 million due to tariffs. The Other category, including Nuclear and Precision Health Solutions, surged with revenue up 31% to $1.7 billion and profit up 34%.

The company updated fiscal 2026 guidance, narrowing and raising non-GAAP diluted EPS to $10.70-$10.80, with improved segment profit growth projections for Pharmaceutical (22-23%) and Other (36-38%). Adjusted free cash flow outlook was lifted to $3.3-$3.7 billion.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Following the April 30 release, Cardinal Health shares initially jumped about 1.6% in pre-market trading on the EPS beat and raised guidance, reflecting positive investor focus on profitability momentum. Intraday, the stock experienced some volatility, dipping 1.4% amid the revenue shortfall and GAAP impairment concerns, but sentiment remains constructive given the full-year outlook upgrade and share repurchase progress. Analysts noted the resilience in high-margin businesses as a key driver outweighing headwinds like tariffs.

Forward Outlook and Key Factors to Monitor

Cardinal Health's raised fiscal 2026 guidance points to continued strength, with non-GAAP EPS expected at $10.70-$10.80 and robust segment growth in Pharmaceutical and Specialty Solutions (22-23%) alongside Other businesses (36-38%). Investors should track execution against these targets, particularly as the company narrows its non-GAAP effective tax rate to around 19% and maintains disciplined share count at 237 million diluted shares.

In the Medical segment, monitor tariff-related pressures, which already impacted Q3 profits; mitigation strategies and volume recovery will be pivotal. Growth in at-home solutions, bolstered by the Advanced Diabetes Supply acquisition, and expansions in Nuclear and Precision Health Solutions—such as increased Actinium-225 production—offer upside potential amid rising demand for specialized therapies.

Balance sheet health remains solid, with leverage at 3.0x following debt paydowns and $1 billion in YTD repurchases. Broader factors include generics pricing trends, specialty pharma demand, and logistics efficiencies via OptiFreight. Upcoming Q4 results in August will provide further clarity on year-end trajectory and any guidance refinements.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations